C2. Antiplatelet agents, vitamin K antagonists, direct thrombin inhibitors, or factor Xa inhibitors with concurrent significant bleeding risk, i.e., uncontrolled severe hypertension, bleeding diathesis, and recent nontrivial spontaneous bleeding (high risk of bleeding). Here, F10 is linked to Hypertension.